The bill amends the Internal Revenue Code and the Affordable Care Act to extend and reshape the enhanced premium tax credit (PTC) for tax years 2026–2027, expands eligibility thresholds for the credit up to 700% of the federal poverty line for those years, and introduces a $5 monthly floor for the lowest-income enrollees. It also directs administrative changes at federally run Exchanges to reduce fraudulent enrollments and require upfront verification when agents or brokers submit enrollments.
On the delivery side, the bill imposes a sweeping transparency and pass-through framework on pharmacy benefit managers (PBMs) in Medicare Part D and MA–PD plans, creates audit and reporting duties, and amends ERISA liability and contract rules to require rebate remittance to group plans. It also makes Exchange enrollees HSA-eligible, allows limited prepayment of premiums, and gives enrollees an option to direct half their advance PTC payments into an HSA.
At a Glance
What It Does
Extends and modifies the temporary enhanced premium tax credit for taxable years beginning after 2025 through 2027 with income-based premium caps (including a $5 contribution floor for the lowest tier), raises the upper eligibility threshold to 700% of the federal poverty line for those years, and mandates verification and tougher penalties for agent/broker misconduct in federally run Exchanges. It requires PBMs in Part D and MA–PD to pass through rebates to plan sponsors, submit detailed annual reports, submit to audits, and face disgorgement and enforcement if they retain prohibited remuneration.
Who It Affects
Individual market enrollees receiving premium tax credits (especially those under 150–700% of FPL), agents/brokers and field/third‑party marketing organizations participating in Exchanges, PBMs and their affiliates, Medicare Part D and MA–PD plan sponsors and auditors, ERISA-regulated group health plans and fiduciaries, pharmacies, manufacturers, and federal agencies (CMS, IRS, HHS, OIG).
Why It Matters
It materially changes affordability mechanics for subsidized consumers for 2026–2027, shifts compliance and transparency obligations onto PBMs and broker networks, and alters fiduciary expectations for plan sponsors — creating material operational, reporting, and contractual changes across the health insurance and prescription drug supply chains.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill operates on three main axes: affordability, anti-fraud/consumer safeguards in Exchanges, and pharmacy supply‑chain accountability. On affordability, it extends the ‘enhanced’ premium tax credit beyond the prior temporary window and rewrites the percentages used to cap enrollee contributions.
For tax years beginning after 2025 and before 2028, enrollees at or below 150% of the poverty line will face a $5 monthly contribution cap (the statute structures the premium assistance calculation to make the enrollee contribution essentially $5). Between 150% and 200% of poverty the contribution phases up on a linear scale; for incomes above 200% through 700% of poverty the bill imposes a new tiered table of initial and final premium percentages so that many middle-income households remain eligible for some advance credit in 2026–2027.
To limit fraudulent enrollments and enrollment churn driven by some agent/broker practices, the bill gives the Secretary authority to require verification for agent- or broker-submitted enrollments in federally run Exchanges. It conditions commission payments on resolution of inconsistencies, requires standardized consent/documentation from brokers, mandates consumer-facing account access and notices, and requires Exchanges to check the Death Master File quarterly to remove deceased enrollees.
The bill raises civil penalties (negligent agent/broker failures: $10,000–$50,000 per affected individual; knowing fraud: up to $200,000 per individual) and adds criminal penalties up to 10 years for willful fraud. For federally operated Exchanges, the Secretary may terminate agent agreements for cause on a preponderance-of-the-evidence standard and must publish audit processes and lists of suspended or terminated agents.On prescription drugs and PBMs, the bill creates a phased, prescriptive transparency and pass-through regime anchored in Medicare Part D and MA–PD rules and extended in ERISA to group plans.
For PDPs and MA–PDs, PBMs must contractually remit rebates, fees, discounts and other remuneration related to utilization of covered drugs to plan sponsors (with narrow bona fide service‑fee exceptions). PBMs must provide standardized, machine‑readable annual reports at drug-level granularity (NDCs, unit counts, wholesale acquisition cost equivalents, rebates and retained revenue by PBM/affiliate, pharmacy reimbursement broken out by channel, lists of affiliates and third-party contractors, etc.), accept independent audits chosen by the plan sponsor, and face disgorgement and civil remedies for noncompliance.
The legislation also directs GAO and MedPAC studies and reports to Congress on price-related compensation structures, and provides CMS and HHS with funding to stand up oversight and enforcement activities.Finally, the bill broadens access to health savings accounts by treating qualified Exchange enrollees as HSA-eligible (subject to coordination rules and limits) and creates two consumer-facing options: a modest prepayment mechanism tied to the premium assistance calculation (a $5 multiplier designed to reduce monthly enrollee liability for those eligible) and an elective mechanism for eligible enrollees to have 50% of their monthly advance premium tax credit deposited directly into their HSA (up to the annual HSA contribution limit). Treasury and HHS must report back within a year on implementing the HSA provisions and on expanding HSA accessibility.
The Five Things You Need to Know
The bill extends enhanced premium tax credit rules for taxable years beginning after Dec. 31, 2025 and before Jan. 1, 2028 and creates a $5 monthly maximum enrollee contribution floor for households at or below 150% of FPL.
For tax years 2026–2027 the eligibility cap described in current law (400% of FPL) is temporarily raised to 700% of FPL, with a new tiered schedule for applicable premium percentages for enrollees above 200% of FPL.
Federally run Exchanges must implement enrollment verification for agent- or broker-submitted enrollments, with commission payments deferred until inconsistencies are resolved and with civil penalties ($10k–$50k negligent; up to $200k knowing) plus criminal exposure for willful broker fraud.
PBMs in Part D and MA–PD plans must pass 100% of rebates/price concessions related to utilization through to PDP sponsors/plan sponsors (subject to narrowly defined bona fide service fees), produce detailed drug-level annual reports in standardized machine-readable formats, and submit to independent audits.
Qualified Exchange enrollees are treated as HSA-eligible and can elect to have 50% of their advance premium tax credit deposited monthly into an HSA (subject to annual HSA limits); the bill also permits a small annual premium prepayment option tied to a $5 multiplier.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Extend and modify enhanced premium tax credit
This section rewrites IRC section 36B temporary rules for years after 2025 and before 2028: it creates a $5 enrollee-contribution floor for households at ≤150% of FPL, phases contribution amounts linearly between 150% and 200% of FPL, and adopts a new tier table for incomes above 200% up to 700% of FPL. It also amends the rule that previously barred credits above 400% of FPL by permitting credits to taxpayers with income up to 700% of FPL for the same temporary period. Practically, this is a targeted affordability expansion for 2026–2027 that preserves the statutory credit architecture but changes the percentages and eligibility bands used to calculate advance and refundable credits.
Exchange fraud guardrails, broker penalties, verification, and deceased‑member checks
This multi-part section tightens the compliance framework for agents, brokers, field marketing organizations and third‑party marketing organizations. It establishes civil penalties for negligent and knowing misreporting by agents/brokers, adds felony-level criminal penalties for willful fraud, and gives federal Exchanges authority to require documentation/consent for broker-submitted enrollments, delay commission payments until data inconsistencies are resolved, and provide consumer-facing account access and notification. It also mandates quarterly Death Master File checks to identify and remove deceased enrollees and requires CMS to implement audits, share suspended/terminated agent lists, and permit termination of broker agreements on a preponderance-of-evidence standard for federally operated Exchanges.
Open enrollment window for plan year 2026
The Secretary must set the 2026 annual open enrollment period to run November 1, 2025 through March 1, 2026. That change lengthens the calendar enrollment window for the 2026 plan year for federally operated Exchanges, which affects marketing and operational timelines for issuers and agents, as well as the timing of subsidy determinations and premium collection.
PBM transparency, reporting, audits and Part D/MA–PD requirements
This large and detailed section adds a Part D/MA–PD‑level subsection requiring PDP sponsors to contract with PBMs that meet multiple transparency and conduct rules for plan years beginning January 1, 2029. PBMs must limit revenue to bona fide flat service fees except where clearly permitted incentive payments are disclosed and consistent with fair market value; they must pass through manufacturer rebates to plan sponsors where applicable; submit standardized, drug-level annual reports (NDC, utilization, costs, rebates, retained revenue, channel-specific reimbursement, affiliate dispensing percentages, DIR-style reporting, contracting counterparty lists); allow independent audits selected by plan sponsors; and accept disgorgement where prohibited remuneration is retained. CMS and OIG are given enforcement and oversight roles, and resources are appropriated to stand up the program.
ERISA safe harbor and full rebate pass-through for group plans
This amendment to ERISA section 408 conditions the reasonableness of pharmacy benefit management contracts on full remittance of rebates and related remuneration to group health plans or their issuers for contracts entered or renewed after a 30‑month implementation window. It creates a narrow innocent-fiduciary safe harbor (if the sponsor reasonably believed remittance occurred and takes specified steps once it learns of non‑remittance), imposes quarterly remittance timing and audit availability, allows plan-selected auditors, and clarifies that bona fide flat fees are permitted where transparent. The change is designed to shift contract economics to sponsors and give them audit rights while preserving limited contracting flexibilities.
HSA eligibility for Exchange enrollees, premium prepayment, and directing PTC into HSAs
Section 7 treats qualified Exchange enrollees as HSA-eligible individuals for purposes of section 223 (with coordination rules to prevent double counting of HSA contributions that result from other advance premium payments). Section 8 creates two options: a modest prepayment mechanism tied to the $5 figure described in the premium credit calculation (allowing individuals to prepay an annual premium multiple of $5) and an elective split of advance premium tax credit payments where 50% of the monthly advance credit is paid to the issuer and 50% is deposited directly into the enrollee’s HSA (subject to annual HSA contribution limits). Treasury and HHS must jointly report within one year on implementation and broader HSA access.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Low‑income Exchange enrollees (≤150% FPL): Faces a de facto $5 monthly maximum contribution under the temporary rules for 2026–2027, substantially lowering out‑of‑pocket premium exposure and improving near‑term affordability for the lowest-income enrollees.
- Middle‑income subsidized households (200%–700% FPL for 2026–2027): Retains or gains eligibility for at least partial premium assistance in 2026–2027 because the bill extends credits and raises the upper eligibility threshold to 700% of FPL for that period.
- Plan sponsors and ERISA fiduciaries seeking clarity: Gain explicit contractual and audit rights to see PBM rebate flows, and an innocent‑fiduciary safe harbor when they reasonably rely on third‑party remittances and act promptly upon discovering shortfalls.
- Consumers who enroll via brokers in federally run Exchanges: Receive additional safeguards — required consent/verification documents, timely notices about premium tax credits prior to enrollment, and clearer routes to cancel unauthorized enrollments.
- HSA‑minded enrollees: Qualified Exchange enrollees can open and fund HSAs and elect to route a portion of advance premium assistance into an HSA, making tax-advantaged savings available to more marketplace participants.
Who Bears the Cost
- Pharmacy benefit managers and affiliates: Face contract changes requiring rebate pass‑through, detailed drug‑level reporting, audit exposure, disgorgement risk, and restrictions on revenue models that were previously opaque or percentage-based.
- Agents, brokers, and field/third‑party marketing organizations: New verification, documentation and reporting obligations, increased civil and criminal exposure for misconduct, and operational burdens around retained commissions and consent records.
- Group health plan sponsors and third‑party administrators: Administrative costs to exercise new audit rights, evaluate PBM contracts, and implement quarterly reconciliation and remittance monitoring; potential liability exposure where pass‑throughs were not properly enforced.
- Manufacturers and rebate aggregators: Additional disclosure requirements and likely operational changes to how price concessions are reported and routed through rebate aggregators, with potential impacts on negotiating leverage.
- CMS, HHS, Treasury, OIG and state departments of insurance: Expanded implementation, audit and enforcement duties; the bill provides appropriations for some HHS/CMS/OIG activities but requires new program design and ongoing resources.
Key Issues
The Core Tension
The central dilemma is the trade-off between greater consumer protection and price transparency on one hand, and market stability and negotiated discount mechanics on the other: forcing full rebate pass-throughs and detailed disclosure aims to reduce net drug costs and hidden revenue streams, but it threatens existing business models that subsidize lower premiums and may prompt pricing, network, or service shifts that offset intended savings; similarly, aggressive broker enforcement reduces fraud risk but can shrink assistance channels that many vulnerable consumers rely upon.
The bill advances three powerful but operationally heavy objectives—short-term affordability, enrollment integrity, and drug‑supply‑chain transparency—that interact in complex ways. Rewriting PTC percentages and extending eligibility to higher income tiers for two years reduces near‑term uninsured risk but risks increasing gross subsidy spending; whether lower enrollee caps (the $5 floor) or altered percentages ultimately reduce premiums or shift costs into other areas will depend on insurer pricing responses.
The PBM and ERISA pass-through mandates are precise about remittance timing and audit access, but translating detailed contract and drug-level disclosure into meaningful price reductions for beneficiaries depends on enforcement fidelity, CMS’ ability to review large datasets, and whether plan sponsors use their new powers to renegotiate benefit designs. There is a material risk that PBMs and insurers will respond by adjusting network designs, formulary placements or premium structures in ways that offset intended savings.
Implementation details present thorny questions. The bill requires machine‑readable, granular PBM disclosures but simultaneously protects confidential commercial terms from public identification — striking the right balance between transparency for regulators/plan sponsors and protection of proprietary contracting information will be hard and litigation-prone.
The HSA mechanics (depositing 50% of advance PTC into an HSA) create tax coordination complexities, especially when enrollees later reconcile credits on tax returns or when individuals switch plans mid-year; Treasury and HHS reports are required, but practical guidance (for example, how to handle excess deposits or ineligible HSA uses) will be needed. Finally, the expanded civil and criminal penalties for agents and brokers may deter bad actors but will also increase compliance costs and could reduce agent-assisted enrollment availability for seniors, limited‑English speakers, and other populations that rely on in-person help unless Exchanges and states fund alternative navigator capacity.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.